biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > June 27, 2023

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jun 09, 2023 12:14am

193 Views

Post# 35487859

RE:RE:RE:June 27, 2023

Biodexa positioned Hunter as its lead xB3 asset and was to have Hunter data to disclose recently. With the scale of Biodexa, and backing of Armistice Capital, a second LSD deal with Chiesi could have been supported as Chiesi becomes a strategic player in LSDs and validates xB3. Add the potential multi-product option exercise with J&J. Biodexa could have been beautiful and provided the scale to make BTI a strong player. It would be on NASDAQ right now. It could have cancer assets too as Midatech's glioblastoma asset nears key data.

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload